BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
Background Mismatch repair deficiency (dMMR) is a well-recognized biomarker for response to immune checkpoint blockade (ICB). Strategies to convert MMR-proficient (pMMR) to dMMR phenotype with the goal of sensitizing tumors to ICB are highly sought. The combination of bromodomain containing 4 (BRD4)...
Main Authors: | Li Zhang, Xi Li, Gang Chen, Yu Fu, Bin Yang, Wenting Li, Jingbo Liu, Xu Qin, Gordon B Mills, Yaoyuan Cui, Xingyuan Hu, Funian Lu, Tianyu Qin, Zhe Hu, Ensong Guo, Junpeng Fan, Rourou Xiao, Dianxing Hu, Wenju Peng, Beibei Wang, Chaoyang Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-04-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/11/4/e006070.full |
Similar Items
-
DNA mismatch repair deficient (dMMR) endometrial cancer
by: Chia-Hao Liu, et al.
Published: (2022-09-01) -
A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
by: Zhu J, et al.
Published: (2023-02-01) -
Overview on population screening for carriers with germline mutations in mismatch repair (MMR) genes in China
by: Min Zhang, et al.
Published: (2021-05-01) -
Lost opportunities for mismatch repair (MMR) screening among minority women with endometrial cancer
by: Marilyn Huang, et al.
Published: (2021-06-01) -
MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC
by: Xucui Zhuang, et al.
Published: (2023-09-01)